Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Feb 16, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2017-02-06

Reporting Person: Patton Stephana Eilene (General Counsel)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$3.05	2027-02-05	Common Shares (250000)		Direct

Footnotes

F1: One quarter of the options shall vest on February 5, 2018 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.